Related Experiment Videos

Pharmacokinetics of intramuscularly administered ertapenem

Donald G Musson1, Anup Majumdar, Kimberly Birk

  • 1Merck Research Laboratories, West Point, Pennsylvania 19486, USA. don_musson@merck.com

Insights

Ertapenem, a once-daily beta-lactam antimicrobial, shows 92% bioavailability via intramuscular injection compared to intravenous administration. This effective antibiotic does not accumulate with repeated daily dosing.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Antibiotic Therapy

Background:

  • Ertapenem is a once-daily parenteral beta-lactam antimicrobial.
  • It is effective as a single agent for various community-acquired and mixed infections.

Purpose of the Study:

  • To compare the plasma pharmacokinetics of a 1-g intramuscular (i.m.) dose of ertapenem.
  • To compare it with 1-g intravenous (i.v.) doses infused over 30 and 120 minutes.

Main Methods:

  • A three-period crossover study in 26 healthy subjects.
  • Single doses administered i.m., i.v. over 30 min, and i.v. over 120 min.
  • Blood samples collected over 24 hours postdose for analysis.

Main Results:

  • The relative bioavailability of the 1-g i.m. dose was 92% compared to the 120-min i.v. infusion.
  • Area under the concentration-time curve (AUC) was comparable between i.m. and 120-min i.v. doses.
  • Ertapenem did not accumulate after 7 days of once-daily 1-g i.m. dosing.

Conclusions:

  • Intramuscular ertapenem provides comparable systemic exposure to intravenous administration.
  • The pharmacokinetic profile supports once-daily intramuscular dosing for ertapenem.
  • Ertapenem is a viable treatment option for infections requiring parenteral beta-lactam therapy.

Related Concept Videos